Myriad Genetics (MYGN) Net Income towards Common Stockholders (2009 - 2026)
Myriad Genetics (MYGN) reported Net Income towards Common Stockholders of -$34.1 million for Q1 2026, down 34000.0% year-over-year from N/an in Q1 2025, and down 331.65% quarter-over-quarter from -$7.9 million in Q4 2025.
Myriad Genetics (MYGN) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Myriad Genetics (MYGN) has 18 years of Net Income towards Common Stockholders data on file, last reported at -$34.1 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$34.1 million, down 34000.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$399.9 million (down 294.38% YoY), and the FY2025 annual result was -$365.9 million, down 187.43% from the prior year.
- Net Income towards Common Stockholders eased to -$34.1 million in Q1 2026 per MYGN's latest filing, from -$7.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$100000.0 in Q1 2025 and troughed at -$330.5 million in Q2 2025.
- A 5-year average of -$53.1 million and a median of -$34.1 million in 2026 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders surged 99.62% in 2025, then plunged 34000.0% in 2026.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$42.3 million in 2022, then rose by 26.24% to -$31.2 million in 2023, then tumbled by 36.22% to -$42.5 million in 2024, then soared by 81.41% to -$7.9 million in 2025, then sank by 331.65% to -$34.1 million in 2026.
- Business Quant data shows MYGN's Net Income towards Common Stockholders at -$34.1 million in Q1 2026, -$7.9 million in Q4 2025, and -$27.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 30,010.71 Bn | 30,010.25 Bn | 1.11 Bn | -72.00 Mn |
| 2 | Thermo Fisher Scientific | 179.46 Bn | 176.21 Bn | 7.74 Bn | 1.66 Bn |
| 3 | Danaher | 130.33 Bn | 124.64 Bn | 3.59 Bn | 1.03 Bn |
| 4 | Idexx Laboratories | 44.44 Bn | 44.24 Bn | 722.74 Mn | 278.45 Mn |
| 5 | Agilent Technologies | 37.27 Bn | 35.46 Bn | 990.00 Mn | 339.00 Mn |
| 6 | Iqvia Holdings | 30.70 Bn | 28.73 Bn | 1.36 Bn | 141.00 Mn |
| 7 | Natera | 30.59 Bn | 29.49 Bn | 696.04 Mn | -85.11 Mn |
| 8 | Illumina | 24.86 Bn | 23.71 Bn | 721.00 Mn | 134.00 Mn |
| 9 | Mettler Toledo International | 23.06 Bn | 23.00 Bn | 555.82 Mn | 169.45 Mn |
| 10 | Myriad Genetics | 414.15 Mn | 289.75 Mn | 137.60 Mn | -34.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.10 Mn |
| Dec 31, 2025 | -7.90 Mn |
| Sep 30, 2025 | -27.40 Mn |
| Jun 30, 2025 | -330.50 Mn |
| Mar 31, 2025 | -100,000.00 |
| Dec 31, 2024 | -42.50 Mn |
| Sep 30, 2024 | -22.10 Mn |
| Jun 30, 2024 | -36.70 Mn |
| Mar 31, 2024 | -26.00 Mn |
| Dec 31, 2023 | -31.20 Mn |
| Sep 30, 2023 | -61.30 Mn |
| Jun 30, 2023 | -116.10 Mn |
| Mar 31, 2023 | -54.70 Mn |
| Dec 31, 2022 | -42.30 Mn |
| Sep 30, 2022 | -35.10 Mn |
| Jun 30, 2022 | -14.10 Mn |
| Mar 31, 2022 | -20.50 Mn |
| Dec 31, 2021 | -7.60 Mn |
| Sep 30, 2021 | 24.60 Mn |
| Jun 30, 2021 | -4.70 Mn |